Ouyang Mengling, Zou Shupeng, Cheng Qian, Shi Xuan, Zhao Yazheng, Sun Minghui
Department of Pharmacy, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei Province, China.
Ther Adv Drug Saf. 2024 Jul 31;15:20420986241260211. doi: 10.1177/20420986241260211. eCollection 2024.
Prolonged or excessive use of acid suppressants may increase the risk of infection (CDI) by altering the intestinal microecosystem. Vonoprazan, a novel potassium-competitive acid blocker, exhibits a faster and more sustained acid-suppressive effect than proton pump inhibitors (PPIs). Therefore, vonoprazan may have a greater impact on the gut microbiota, potentially resulting in CDI.
This study aimed to explore the potential relationship between acid suppressants and CDI by the Japan Adverse Drug Event Report (JADER) and the FDA Adverse Event Reporting System (FAERS) databases.
A retrospective analysis of the JADER and FAERS databases was examined by disproportionality analysis.
We performed signal detection analyses of CDI induced by vonoprazan and PPIs using the JADER and FAERS databases. The association between acid suppressants and CDI was calculated using the reporting odds ratio (ROR) and corresponding 95% confidence interval (95% CI). When the lower limit of the 95% CI is exceeded by 1, the association is considered statistically significant.
In the JADER database, the ROR (95% CI) for vonoprazan and PPIs based on suspect drug reports was 15.84 (12.23-20.50) and 2.51 (1.92-3.28), respectively. In the FAERS database, the ROR (95% CI) for vonoprazan and PPIs based on primary and secondary suspect drug reports was 11.50 (6.36-20.82) and 1.42 (1.34-1.51), respectively. Subgroup analysis showed that elderly patients aged 60 years and older were more strongly associated with CDI. The ROR (95% CI) for vonoprazan and PPIs in patients aged 60 years and older in the JADER database was 15.35 (11.59-20.33) and 1.65 (1.14-2.39), respectively. Similarly, the ROR (95% CI) for vonoprazan and PPIs in the FAERS database was 12.56 (6.26-25.20) and 1.43 (1.31-1.57), respectively. Excluding the effect of () infection, the use of acid suppressants was still associated with CDI.
While signal detection analysis based on the JADER and FAERS databases could not establish causality, our study demonstrated that both vonoprazan and PPIs were significantly associated with CDI. Vonoprazan showed a stronger association with CDI in both databases.
长期或过度使用抑酸剂可能通过改变肠道微生态系统增加感染艰难梭菌(CDI)的风险。沃克拉唑是一种新型钾离子竞争性酸阻滞剂,其抑酸作用比质子泵抑制剂(PPI)更快且更持久。因此,沃克拉唑可能对肠道微生物群有更大影响,有可能导致CDI。
本研究旨在通过日本药品不良反应事件报告(JADER)数据库和美国食品药品监督管理局不良事件报告系统(FAERS)数据库探索抑酸剂与CDI之间的潜在关系。
通过不成比例分析对JADER和FAERS数据库进行回顾性分析。
我们使用JADER和FAERS数据库对沃克拉唑和PPI引起的CDI进行信号检测分析。使用报告比值比(ROR)和相应的95%置信区间(95%CI)计算抑酸剂与CDI之间的关联。当95%CI的下限超过1时,该关联被认为具有统计学意义。
在JADER数据库中,基于可疑药物报告的沃克拉唑和PPI的ROR(95%CI)分别为15.84(12.23 - 20.50)和2.51(1.92 - 3.28)。在FAERS数据库中,基于主要和次要可疑药物报告的沃克拉唑和PPI的ROR(95%CI)分别为11.50(6.36 - 20.82)和1.42(1.34 - 1.51)。亚组分析表明,60岁及以上的老年患者与CDI的关联更强。在JADER数据库中,60岁及以上患者中沃克拉唑和PPI的ROR(95%CI)分别为15.35(11.59 - 20.33)和1.65(1.14 - 2.39)。同样,在FAERS数据库中,沃克拉唑和PPI的ROR(95%CI)分别为12.56(6.26 - 25.20)和1.43(1.31 - 1.57)。排除()感染的影响后,抑酸剂的使用仍与CDI相关。
虽然基于JADER和FAERS数据库的信号检测分析无法确定因果关系,但我们的研究表明,沃克拉唑和PPI均与CDI显著相关。在两个数据库中,沃克拉唑与CDI的关联更强。